The spread of the Coronavirus (COVID-19) continues to present serious challenges to the healthcare industry. On August 25th, CMS posted a new interim final rule with comment period (IFR). The new IFR outlined multiple changes intended to address the ongoing impact of COVID-19, including additional changes to the Medicare Advantage (MA) 2022 Part C and D Star Ratings impacting 2023 payment year.

This whitepaper outlines CMS’ latest modifications to the 2022 Star Ratings, quantifies the impact on 2023 MA spending, and discusses how these changes may influence the MA market in 2023.

How will COVID-19 impact Medicare Advantage spending due to Star Rating changes?